What do NAbs mean for my MS therapy?

How can NAbs affect your MS therapy? This is an ongoing area of study, and we do not yet have a complete understanding of the effects of NAbs on MS treatment. However, knowledge in this area has come a long way in recent years. Here's what we do know:

NAbs may make your interferon medication less effective. Some people taking interferon medications, such as Avonex® (interferon beta-1a once weekly), Rebif® (interferon beta-1a three times weekly), or Betaseron® (interferon beta-1b), find that NAbs may decrease the effectiveness of their treatment, with effects including:

  • higher relapse rates
  • more active MS as shown on MRI scans
  • higher rates of disease progression

The effects of NAbs sound alarming, but there are a few things to keep in mind:

  • NAbs do not always make your treatment less effective and they are not the only factor that determines whether your treatment will be effective. People with high levels of NAbs that continue over long periods of time are most at risk of decreased treatment effectiveness.
  • NAbs take time to develop, and it can be years before they affect your treatment. NAbs usually appear after 12-18 months of treatment. But one study has found that the NAbs did not start to have a significant effect on treatment effectiveness until about 4 years of treatment.
  • Many people with NAbs find that the NAbs go away on their own over time. NAbs are more likely to go away if you have low NAb levels.

It's important to understand that testing positive for NAbs does not mean that you will need to stop or change your MS treatment. In deciding whether to switch treatment, you and your doctor will need to consider your symptoms and MRI test results to see whether the NAbs are affecting your response to the medication. If your medication is still working well for you, there may be no need for a change. If your medication is not working as well as it once did, and you have tested positive for NAbs more than once, switching to a non-interferon medication such as glatiramer may be an option.

If you are concerned about NAbs, talk to your doctor for more information and guidance.

NAbs are an active area of MS research. Ongoing research should help to answer these and other questions. It will also help us gain a better understanding of why and how NAbs affect MS therapy and what can be done about them.

All material copyright MediResource Inc. 1996 – 2021. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www.medbroadcast.com/healthfeature/gethealthfeature/MS-The-Role-of-NAbs